Problem

Artos addresses the slow, expensive production of regulatory and medical-writing documents for life-sciences companies. INDs, PMAs, and related submissions can run to thousands of pages, and teams must compile, review, cite, and reformat large volumes of clinical, non-clinical, CMC, and other product data. That work can add weeks or months to development timelines, while companies either spend heavily on contractors or commit hundreds of internal hours to drafting.

The killer use case is turning a product’s underlying data and reports into the first drafts required for regulatory submissions, such as INDs, NDAs, BLAs, and medical-device filings. Because these submissions are a final hurdle before a product can be sold, reducing drafting time can accelerate market access and lower the cost of bringing a therapy or device to market.

Product / Service

Artos is an AI-powered document-creation and management platform for life sciences. It synthesizes company data into high-quality first drafts and provides an end-to-end workflow across the CTD pyramid, rather than functioning as a standalone text-generation tool. Its stated coverage includes clinical and non-clinical overviews and summaries, tabulated summaries, quality overall summaries, clinical study reports, investigator brochures, analytical validations, and other submission documents.

The platform is designed to support the full document lifecycle and collaborative work across medical writing, CMC, regulatory affairs, and regulatory intelligence teams. Features include document search, source traceability, custom templates, section regeneration, audit logs, automated workflows, downstream visualization, and the ability to propagate changes across related documents. Artos says this approach can put submission documents together in roughly half the time, while keeping sensitive company data secure; the company currently uses a demo-led commercial motion.

Market

Artos competes in the emerging market for generative-AI medical writing, regulatory-authoring software, and life-sciences submission content management. The closest evidenced alternatives include Certara’s CoAuthor, which uses biomedical GPT, eCTD templates, structured content, and Microsoft Word integration for regulatory and medical writing, and Yseop Copilot, which supports AI-driven document generation across the CTD pyramid and integrates with Veeva Vault RIM. Artos’s positioning is broader than a single drafting assistant: it emphasizes one suite spanning document creation, management, traceability, and collaboration across the submission lifecycle.

Public evidence indicates an early-stage company rather than a mature scaled vendor. Artos was founded in 2023, participated in Y Combinator’s Winter 2024 batch, and had seven employees in San Francisco in the available company profile. A third-party funding record reports a $500,000 seed round announced in February 2024. The public materials reviewed show a live product and a “Book a demo” sales motion, but do not disclose customer counts or revenue, so Artos cannot be reliably classified as either revenue-generating or pre-revenue from the available evidence alone.